Davide Massimi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2838714/publications.pdf Version: 2024-02-01



DAVIDE MASSIMI

#	Article	IF	CITATIONS
1	Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation. Intestinal Research, 2022, 20, 114-123.	2.6	12
2	A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach. Gut Microbes, 2022, 14, 2028366.	9.8	26
3	A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110314.	3.2	10
4	Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. Scientific Reports, 2021, 11, 10368.	3.3	21
5	Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Gastroenterology, 2021, 161, 1865-1877.	1.3	46
6	Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110233.	3.2	7
7	Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study. Digestive Diseases, 2021, 39, 16-24.	1.9	12
8	Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093431.	3.2	6
9	Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093458.	3.2	7
10	Medical and gastroenterological education during the COVID-19 outbreak. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 447-449.	17.8	18
11	Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. Clinical and Translational Gastroenterology, 2020,	2.5	14